We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthpeak's Q3 FFO Beats Estimates, Same-Store NOI Rises
Read MoreHide Full Article
Healthpeak Properties, Inc. (DOC - Free Report) reported third-quarter 2024 funds from operations (FFO) as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. The reported figure remained unchanged from the prior-year quarter.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Results reflected better-than-anticipated revenues. Growth in total merger-combined same-store cash (adjusted) net operating income (NOI) was witnessed across the portfolio. However, higher interest expenses undermine the results to an extent. The company revised its 2024 outlook.
This healthcare real estate investment trust (REIT) generated revenues of $700.4 million, outpacing the Zacks Consensus Estimate of $689 million. The figure climbed 25.9% year over year.
Healthpeak Properties, Inc. Price, Consensus and EPS Surprise
In the third quarter, Healthpeak reported 4.1% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI.
It witnessed 3.4% and 2.8% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI for its outpatient medical and lab segments, respectively. The CCRC segment reported growth of 14.2%.
During the reported quarter, Healthpeak executed 465,000 square feet of lab leases. For the outpatient medical portfolio, new and renewal leases aggregated 3 million square feet. The company achieved a positive 10% cash rent mark-to-market on renewals for both of the above portfolios.
During the third quarter, Healthpeak started a $37 million, 79,000-square-foot Class A outpatient medical development in Kansas City, 100% pre-leased to HCA.
However, interest expenses jumped 46.7% year over year to $74.1 million.
DOC’s Balance Sheet
Healthpeak exited the third quarter with cash and cash equivalents of $180.4 million, up from $106.9 million as of June 30, 2024. Its net debt to adjusted EBITDAre was 5.1X as of Sept. 30, 2024.
Healthpeak’s Dividend Update
On Oct. 23, Healthpeak’s board of directors announced a quarterly cash dividend of 30 cents per common share. The dividend will be paid out on Nov. 15 to shareholders on record as of Nov. 4, 2024.
DOC’s 2024 Outlook
Healthpeak revised its guidance for FFO as adjusted per share to the range of $1.79-$1.81 from the $1.77-$1.80 range estimated earlier, raising the midpoint by 1 cent. The Zacks Consensus Estimate is presently pegged at $1.79, which is within expectations.
The total merger-combined same-store cash (adjusted) NOI growth is revised and estimated to be in the range of 3.5-4.5% from 2.75-4.25%, raising the midpoint by 50 basis points.
Healthpeak currently carries a Zacks Rank #3 (Hold).
Upcoming Earnings Releases
We now look forward to the earnings releases of other healthcare REITs, such as Welltower (WELL - Free Report) and Ventas (VTR - Free Report) , slated to report on Oct. 28 and Oct. 30, respectively.
The Zacks Consensus Estimate for Ventas’ third-quarter 2024 FFO per share stands at 80 cents, indicating a 6.7% rise year over year. VTR currently has a Zacks Rank #2.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Healthpeak's Q3 FFO Beats Estimates, Same-Store NOI Rises
Healthpeak Properties, Inc. (DOC - Free Report) reported third-quarter 2024 funds from operations (FFO) as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. The reported figure remained unchanged from the prior-year quarter.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Results reflected better-than-anticipated revenues. Growth in total merger-combined same-store cash (adjusted) net operating income (NOI) was witnessed across the portfolio. However, higher interest expenses undermine the results to an extent. The company revised its 2024 outlook.
This healthcare real estate investment trust (REIT) generated revenues of $700.4 million, outpacing the Zacks Consensus Estimate of $689 million. The figure climbed 25.9% year over year.
Healthpeak Properties, Inc. Price, Consensus and EPS Surprise
Healthpeak Properties, Inc. price-consensus-eps-surprise-chart | Healthpeak Properties, Inc. Quote
Behind DOC’s Earnings Headlines
In the third quarter, Healthpeak reported 4.1% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI.
It witnessed 3.4% and 2.8% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI for its outpatient medical and lab segments, respectively. The CCRC segment reported growth of 14.2%.
During the reported quarter, Healthpeak executed 465,000 square feet of lab leases. For the outpatient medical portfolio, new and renewal leases aggregated 3 million square feet. The company achieved a positive 10% cash rent mark-to-market on renewals for both of the above portfolios.
During the third quarter, Healthpeak started a $37 million, 79,000-square-foot Class A outpatient medical development in Kansas City, 100% pre-leased to HCA.
However, interest expenses jumped 46.7% year over year to $74.1 million.
DOC’s Balance Sheet
Healthpeak exited the third quarter with cash and cash equivalents of $180.4 million, up from $106.9 million as of June 30, 2024. Its net debt to adjusted EBITDAre was 5.1X as of Sept. 30, 2024.
Healthpeak’s Dividend Update
On Oct. 23, Healthpeak’s board of directors announced a quarterly cash dividend of 30 cents per common share. The dividend will be paid out on Nov. 15 to shareholders on record as of Nov. 4, 2024.
DOC’s 2024 Outlook
Healthpeak revised its guidance for FFO as adjusted per share to the range of $1.79-$1.81 from the $1.77-$1.80 range estimated earlier, raising the midpoint by 1 cent. The Zacks Consensus Estimate is presently pegged at $1.79, which is within expectations.
The total merger-combined same-store cash (adjusted) NOI growth is revised and estimated to be in the range of 3.5-4.5% from 2.75-4.25%, raising the midpoint by 50 basis points.
Healthpeak currently carries a Zacks Rank #3 (Hold).
Upcoming Earnings Releases
We now look forward to the earnings releases of other healthcare REITs, such as Welltower (WELL - Free Report) and Ventas (VTR - Free Report) , slated to report on Oct. 28 and Oct. 30, respectively.
The Zacks Consensus Estimate for Welltower’s third-quarter 2024 FFO per share is pegged at $1.04, implying a 13% year-over-year increase. WELL currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Ventas’ third-quarter 2024 FFO per share stands at 80 cents, indicating a 6.7% rise year over year. VTR currently has a Zacks Rank #2.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.